International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Lactobacillus Probiotics: Mechanisms, Health Benefits, and Applications in Combating Pathogenic Bacteria

Mohamed Younes A Hassan, Mahmoud F Gaballa, Mohamed Eid Kotb ZIDAN, Alaa Alrahman DM Abid, Idress Hamad Attitalla

Department of Microbiology, Faculty of Science, Omar Al-Mukhtar, University AL-Bayda, Libya; Director of the General Administration of Occupational Safety and Health, Saudi Arabia; Chemist at Al khorayef Water and Energy Technology Company Al-Ahsa, Saudi Arabia

Article Information

Volume / Issue6 / 3 (July-September 2025)
Pages208-216
AccessOpen Access

Publication Timeline

  • Received02 July 2025
  • Accepted01 August 2025
  • Published

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

This research paper explores the potential of Lactobacillus probiotics as a safe and cost-effective alternative to conventional antibiotics for combating antibiotic-resistant pathogenic bacteria. With the rise of multidrug-resistant pathogens posing a significant threat to global health, there is an urgent need for innovative therapeutic strategies. Probiotics, particularly lactic acid bacteria such as Lactobacillus, offer promising health benefits, including enhancing gut microbiota balance, strengthening immune responses, and producing antimicrobial compounds that inhibit pathogenic bacteria. The study highlights the mechanisms by which Lactobacillus strains exert their beneficial effects, such as competitive exclusion of pathogens, production of bacteriocins, modulation of gut barrier function, and immunomodulation. Additionally, probiotics demonstrate efficacy in treating gastrointestinal disorders, metabolic imbalances, and even chronic conditions like cancer and mental health disorders. Beyond human health, their applications extend to agriculture, where they contribute to sustainable practices by improving plant resilience and soil health. Despite these advantages, further research is needed to optimize strain-specific effects, dosages, and long-term impacts. Collaborative efforts among researchers, clinicians, and policymakers are essential to integrate probiotics into mainstream healthcare and environmental management. Embracing probiotics as part of daily nutrition and therapeutic regimens could revolutionize public health, reduce reliance on antibiotics, and promote ecological sustainability. In conclusion, Lactobacillus and other probiotic bacteria represent a bridge between natural microbial solutions and modern medicine, offering innovative approaches to address global health challenges while aligning with sustainable practices. Continued exploration of their potential promises to unlock new avenues for improving health across diverse ecosystems. 

Keywords

LactobacillusProbioticsAntibiotic ResistanceGut MicrobiotaAntimicrobial MechanismsHealth Benefits

References

  1. Papajk J, Mezerová K, Uvízl R, Štosová T, Kolář M. Clonal diversity of Klebsiella spp. and Escherichia spp. strains isolated from patients with ventilator-associated pneumonia. Antibiotics. 2021;10(6):674. doi:10.3390/antibiotics10060674. [Google Scholar][Crossref]
  2. Hricová K, Štosová T, Kučová P, Fišerová K, Bardoň J, Kolář M. Analysis of vancomycin-resistant enterococci in hemato-oncological patients. Antibiotics. 2020;9(11):785. doi:10.3390/antibiotics9110785. [Google Scholar][Crossref]
  3. Kollef MH, Bassetti M, Francois B, Burnham J, Dimopoulos G, Garnacho-Montero J, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017;43:1187–1197. doi:10.1007/s00134-017-4682-7. [Google Scholar][Crossref]
  4. FAO/WHO. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. 2001. Available from: https://www.fao.org/3/a0512e/a0512e.pdf [Google Scholar][Crossref]
  5. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66. [Google Scholar][Crossref]
  6. Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–667. doi:10.1038/s41575-021-00440-6. [Google Scholar][Crossref]
  7. Liévin-Le Moal V, Servin AL. Anti-infective activities of Lactobacillus strains in the human intestinal microbiota: From probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev. 2014;27(2):167–199. doi:10.1128/CMR.00080-13. [Google Scholar][Crossref]
  8. Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of Lactobacillus. J Clin Pathol. 2016;69(3):187–203. doi:10.1136/jclinpath-2015-202976. [Google Scholar][Crossref]
  9. Herkel T, Uvizl R, Doubravska L, Adamus M, Gabrhelik T, Htoutou Sedlakova M, et al. Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Pap. 2016;160(3):448–455. doi:10.5507/bp.2016.014. [Google Scholar][Crossref]
  10. Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MÁ, Batlle M, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30(3):355–360. doi:10.1007/s10096-010-1093-x. [Google Scholar][Crossref]
  11. Abd El-Gawad IA, El-Sayed EM, Hafez SA, El-Zeini HM, Saleh FA. The hypocholesterolaemic effect of milk yoghurt and soy-yoghurt containing Bifidobacteria in rats fed on a cholesterol-enriched diet. Int Dairy J. 2005;15(1):37–44. doi:10.1016/j.idairyj.2004.06.001. [Google Scholar][Crossref]
  12. Agerholm-Larsen L, Bell ML, Grunwald GK, Astrup A. The effect of a probiotic milk product on plasma cholesterol: A meta-analysis of short-term intervention studies. Eur J Clin Nutr. 2000;54(11):856–860. doi:10.1038/sj.ejcn.1601104. [Google Scholar][Crossref]
  13. Aloha AJ, Yli-Knuuttila H, Suomalainen T, Poussa T, Ahlstrom A, Meurman JH. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch Oral Biol. 2002;47(11):799– 804. doi:10.1016/S0003-9969(02)00112-7. [Google Scholar][Crossref]
  14. Arora M, Sharma S, Baldi A. Comparative insight of regulatory guidelines for probiotics in USA, India and Malaysia: A critical review. Int J Biotechnol Wellness Ind. 2013;2(2):51–64. [Google Scholar][Crossref]
  15. Arseneault-Breard J, Rondeau I, Gilbert K, Girard SA, Tompkins TA, Godbout R, et al. Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. Br J Nutr. 2012;107(12):1793–1799. doi:10.1017/S0007114511005137. [Google Scholar][Crossref]
  16. Benton D, Williams C, Brown A. Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr. 2007;61(3):355–361. doi:10.1038/sj.ejcn.1602546. [Google Scholar][Crossref]
  17. Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil. 2011;23(12):1132–1139. doi:10.1111/j.1365 -2982.2011.01796.x. International Journal of Medical and All Body Health Research www.allmedicaljournal.com [Google Scholar][Crossref]
  18. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050–16055. doi:10.1073/pnas.1102999108. [Google Scholar][Crossref]
  19. Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. 2006;100(4):754–765. doi:10.1111/j.1365-2672.2006.02837.x. [Google Scholar][Crossref]
  20. Chen LJ, Tsai HT, Chen WJ, Hsieh CY, Wang PC, Chen CS, et al. in vitro antagonistic growth effects of Lactobacillus fermentum and Lactobacillus salivarius and their fermentative broth on periodontal pathogens. Braz J Microbiol. 2012;43(4):1376–1384. doi:10.1590/S1517-83822012000400019. [Google Scholar][Crossref]
  21. Chen YP, Hsiao PJ, Hong WS, Dai TY, Chen MJ. Lactobacillus kefiranofaciens M1 isolated from milk kefir grains ameliorates experimental colitis in vitro and in vitro. J Dairy Sci. 2011;95(1):63–74. doi:10.3168/jds.2011-4696. [Google Scholar][Crossref]
  22. Cildar SK, Germec D, Sandalli N, Ozdemir FI, Arun T, Twetman S, et al. Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria. Eur J Orthod. 2009;31(4):407–411. doi:10.1093/ejo/cjn108. [Google Scholar][Crossref]
  23. Cryan JF, Dinan TG. Mind-altering microorganisms: The impact of the gut microbiota on brain and behavior. Nat Rev Neurosci. 2012;13(10):701–712. doi:10.1038/nrn3346. [Google Scholar][Crossref]
  24. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2009;43(2):164–174. doi:10.1016/j.jpsychires.2008.03.009. [Google Scholar][Crossref]
  25. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010;170(4):1179–1188. doi:10.1016/j.neuroscience.2010.08.005. [Google Scholar][Crossref]
  26. Duary RK, Bhausaheb MA, Batish VK, Grover G. Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol Biol Rep. 2011;39(4):4765– 4775. doi:10.1007/s11033-011-1269-1. [Google Scholar][Crossref]
  27. Elgert KD. Immunology: Understanding the Immune System. 2 nd ed. New Jersey: Wiley-Blackwell; 2009. p. 285–292. [Google Scholar][Crossref]
  28. Emms S, Sia. Malaysia’s markets for functional foods, nutraceuticals and organic foods: An introduction for Canadian producers and exporters. Agriculture and Agri-Food Canada. 2011. Available from: http://www.atssea.agr.gc.ca/ase/pdf/5842-eng.pdf [Google Scholar][Crossref]
  29. European Food Safety Authority (EFSA). Opinion of the scientific committee on introduction of a qualified presumption of safety (QPS) approach for assessment of selected microorganisms referred to EFSA. EFSA J. 2007;5(12):1–16. [Google Scholar][Crossref]
  30. Foligné B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, et al. Correlation between in vitro and in vitro immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007;13(2):236– 243. doi:10.3748/wjg.v13.i2.236. [Google Scholar][Crossref]
  31. Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO). Report of a Joint FAO/WHO Working Group on drafting guidelines for the evaluation of probiotics in food. 2002. Available from: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf [Google Scholar][Crossref]
  32. Forssten SD, Lahtinen SJ, Arthur C, Ouwehand AC. The intestinal microbiota and probiotics. In: Malago JJ, Koninkx JFJ, Marinsek-Logar R, editors. Probiotic Bacteria and Enteric Infections. New York: Springer; 2011. p. 11–24. doi:10.1007/978-94-007-0386-5_2. [Google Scholar][Crossref]
  33. Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol. 2013;304(2):G132– G141. doi:10.1152/ajpgi.00142.2012. [Google Scholar][Crossref]
  34. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol. 2011;2:94. doi:10.3389/fphys.2011.00094. [Google Scholar][Crossref]
  35. Gueniche A, Bastien P, Ovigne JM, Kermici M, Courchay G, Chevalier V, et al. Bifidobacterium longum lysate, a new ingredient for reactive skin. Exp Dermatol. 2010;19(8):e1–e8. doi:10.1111/j.1600-0625.2009.00932.x. [Google Scholar][Crossref]
  36. Haukioja A, Loimaranta V, Tenovuo J. Probiotic bacteria affect the composition of salivary pellicle and streptococcal adhesion in vitro. Oral Microbiol Immunol. 2008;23(4):336–343. doi:10.1111/j.1399-302X.2008.00435.x. [Google Scholar][Crossref]
  37. Hojo K, Mizoguchi C, Takemoto N, Oshima T, Gomi K, Arai T. Distribution of salivary Lactobacillus and Bifidobacterium species in periodontal health and disease. Biosci Biotechnol Biochem. 2007;71(1):152– 157. doi:10.1271/bbb.60420. [Google Scholar][Crossref]
  38. Iordache F, Iordache C, Chifiriuc MC, Bleotu C, Pavel M, Smarandache D, et al. Antimicrobial and immunomodulatory activity of some probiotic fractions with potential clinical application. Archiva Zootechnica. 2008;11(3):41–51. [Google Scholar][Crossref]
  39. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr. 2001;73(2):465–470. [Google Scholar][Crossref]
  40. Ishikawa H, Aiba Y, Nakanishi M, Oh-Hashi Y, Koga Y. Suppression of periodontal pathogenic bacteria in the saliva of human by the administration of Lactobacillus salivarius T12711. J Jpn Soc Periodontol. 2003;45(1):105–112. doi:10.2329/perio.45.105. [Google Scholar][Crossref]
  41. Jensen ME, Wefel JS. Effects of processed cheese on human plaque pH and demineralization and remineralization. Am J Dent. 1990;3(5):217–223. [Google Scholar][Crossref]
  42. Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000;78(1):80–88. doi:10.1046/j.1440-1711.2000.00886.x. [Google Scholar][Crossref]
  43. Kang MS, Kim BG, Chung J, Lee HC, Oh JS. Inhibitory effect of Weissella cibaria isolates on the production of volatile sulphur compounds. J Clin Periodontol. 2006;33(3):226–232. doi:10.1111/j.1600-051X.2006.00893.x. [Google Scholar][Crossref]
  44. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. International Journal of Medical and All Body Health Research www.allmedicaljournal.com 2011;474(7351):307–317. doi:10.1038/nature10209. [Google Scholar][Crossref]
  45. Koll-Klais P, Mandar R, Leibur E, Marcotte H, Hammarstrom L, Mikelsaar M. Oral Lactobacillus in chronic periodontitis and periodontal health: Species composition and antimicrobial activity. Oral Microbiol Immunol. 2005;20(6):354–361. doi:10.1111/j.1399-302X.2005.00239.x. [Google Scholar][Crossref]
  46. Krasse P, Carlsson B, Dahl C, Paulsson A, Nilsson A, Sinkiewicz G. Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. Swed Dent J. 2006;30(2):55–60. [Google Scholar][Crossref]
  47. Kumar R, Grover S, Batish VK. Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing Lactobacillus plantarum strains in Sprague–Dawley rats. Br J Nutr. 2011;105(4):561–573. doi:10.1017/S0007114510003740. [Google Scholar][Crossref]
  48. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab. 2010;7:79. doi:10.1186/1743-7075-7-79. [Google Scholar][Crossref]
  49. Lambert JM, Bongers RS, de Vos WM, Kleerebezem M. Functional analysis of four bile salt hydrolase and penicillin acylase family members in Lactobacillus plantarum WCFS1. Appl Environ Microbiol. 2008;74(15):4719–4726. doi:10.1128/AEM.00137-08. [Google Scholar][Crossref]
  50. Leuschner RGK, Robinson TP, Hugas M, Cocconcelli PS, Richard-Forget F, Klein G, et al. Qualified presumption of safety (QPS): A generic risk assessment approach for biological agents notified to the European Food Safety Authority (EFSA). Trends Food Sci Technol. 2010;21(9):425–435. doi:10.1016/j.tifs.2010.07.003. [Google Scholar][Crossref]
  51. Lew LC, Liong MT. Bioactives from probiotics for dermal health: Functions and benefits. J Appl Microbiol. 2013;114(5):1241–1253. doi:10.1111/jam.12137. [Google Scholar][Crossref]
  52. Lye HS, Rahmat-Ali GR, Leong MT. Mechanisms of cholesterol removal by Lactobacillus under conditions that mimic the human gastrointestinal tract. Int Dairy J. 2010;20(3):169–175. doi:10.1016/j.idairyj.2009.10.003. [Google Scholar][Crossref]
  53. Masdea L, Kulik EM, Hauser-Gerspach I, Ramseier AM, Filippi A, Waltimo T. Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. Arch Oral Biol. 2012;57(8):1041–1047. doi:10.1016/j.archoralbio.2012.02.011. [Google Scholar][Crossref]
  54. Matsumoto M, Kibe R, Ooga T, Aiba Y, Sawaki E, Koga Y, et al. Cerebral low-molecular metabolites influenced by intestinal microbiota: A pilot study. Front Syst Neurosci. 2013;7:9. doi:10.3389/fnsys.2013.00009. [Google Scholar][Crossref]
  55. Lay C, Rigottier-Gois L, Holmstrom K, Rajilic M, Vaughan EE, de Vos WM, et al. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol. 2005;71(7):4153–4155. doi:10.1128/AEM.71.7.4153-4155.2005. [Google Scholar][Crossref]
  56. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638. doi:10.1126/science.1110591. [Google Scholar][Crossref]
  57. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031. doi:10.1038/nature05414. [Google Scholar][Crossref]
  58. ILSI Europe. Scientific concepts of functional foods in Europe: Consensus document. Br J Nutr. 1999;81(Suppl 1):1S–27S. [Google Scholar][Crossref]
  59. Strachan DP, Golding J, Anderson HR. Regional variations in wheezing illness in British children: Effect of migration during early childhood. J Epidemiol Community Health. 1990;44(3):231–236. doi:10.1136/jech.44.3.231. [Google Scholar][Crossref]
  60. Holt PG, Macaubas C, Prescott SL, Sly PD. Microbial stimulation as an aetiologic factor in atopic disease. Allergy. 1999;54(Suppl 54):12–16. doi:10.1111/j.1398-9995.1999.tb04382.x. [Google Scholar][Crossref]
  61. Adlerberth I. The establishment of normal intestinal microflora in the newborn infants [PhD Dissertation]. Gothenburg: University of Gothenburg; 1996. [Google Scholar][Crossref]
  62. Bennet R, Eriksson M, Nord CE, Zetterström R. Suppression of aerobic and anaerobic fecal flora in newborns receiving parenteral gentamicin and ampicillin. Acta Paediatr Scand. 1982;71(4):559–562. doi:10.1111/j.1651-2227.1982.tb09474.x. [Google Scholar][Crossref]
  63. Stsepetova J, Sepp E, Julge K, Vaughan E, Mikelsaar M, de Vos WM. Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial communities are characteristic of 5-year-old allergic children. FEMS Immunol Med Microbiol. 2007;51(2):260–269. doi:10.1111/j.1574 -695X.2007.00306.x. [Google Scholar][Crossref]
  64. Sepp E, Voor T, Julge K, Lõivukene K, Björkstén B, Mikelsaar M. Is intestinal microbiota bound up with changing lifestyle? In: Mendez-Vilas A, editor. Modern Multi-disciplinary Applied Microbiology: Exploiting Microbes and Their Interactions. Weinheim: Wiley-VCH; 2006. p. 708–712. [Google Scholar][Crossref]
  65. Björkstén B, Graninger G, Jacobsson Ekman G. New ideas in asthma and allergy research: Creating a multidisciplinary graduate school. J Clin Invest. 2003;112(6):816–820. doi:10.1172/JCI19798. [Google Scholar][Crossref]
  66. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: Underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223–227. doi:10.1097/00005176-200302000-00012. [Google Scholar][Crossref]
  67. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol. 2001;32(1):1–7. doi:10.1111/j.1574-695X.2001.tb00526.x. [Google Scholar][Crossref]
  68. Food and Agriculture Organization (FAO). Guidelines for the evaluation of probiotics in food. 2002. Available from: http://www.who.int/foodsafety/fs_management/e n/probiotic_guidelines.pdf [Google Scholar][Crossref]
  69. Mercenier A, Lenoir-Wijnkoop I, Sanders ME. Physiological and functional properties of probiotics. Bull Int Dairy Fed. 2008;429:2–6. [Google Scholar][Crossref]
  70. Rijkers GT, Watzl B, Rabot S, Rafter J, Antoine JM, Haller D, et al. Guidance for assessing the probiotics beneficial effects: How to fill GAP. ILSI Europe Workshop in Association with the International Dairy Federation. Montreux, Switzerland; 2008. [Google Scholar][Crossref]
  71. Reid G, Kim SO, Kohler GA. Selecting, testing and understanding probiotic microorganisms. FEMS Immunol Med Microbiol. 2006;46(2):149–157. International Journal of Medical and All Body Health Research www.allmedicaljournal.com doi:10.1111/j.1574-695X.2005.00026.x. [Google Scholar][Crossref]
  72. Lu L, Walker WA. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. Am J Clin Nutr. 2001;73(6):1124S–1130S. doi:10.1093/ajcn/73.6.1124S. [Google Scholar][Crossref]
  73. Attitalla IH, Elhai GA, Gaballa MF, Elzlitni RA, Jhones RC, Abid AADM, et al. Exploring the extended pathogenesis of infectious bronchitis virus strain M41: Insights from expected and novel tissue targets in chicks. Acta Tradit Med. 2024;3(1):19–23. [Google Scholar][Crossref]
  74. Gaballa MF. Microbial influence on animal health: The role of gut microbiota, dysbiosis, and probiotic interventions. Int J Interdiscip Multidiscip Stud. 2024;12(2):1–20. [Google Scholar][Crossref]
  75. Attitalla IH, El-Seifat RM, Bufarwa SM, Gaballa MF, Soutiyah MAA, Abdulhafith SA, et al. The role of marine algae as a bioindicator in assessing environmental pollution. J Surv Fish Sci. 2023;10(4S):1837–1869. [Google Scholar][Crossref]
  76. Alsadi I, Zafir AG, Alati MM, Hamad R, Saleh A, Gaballa MF, et al. Risk analysis of brucellosis in country level Libya. J Vet Sci Res. 2023;8(1):1–5. [Google Scholar][Crossref]
  77. Akhreim AA, Gaballa MF, Sulaiman G, Attitalla IH. Biofertilizers production and climate changes on environmental prospective applications for some nanoparticles produced from some microbial isolates. Int J Agric Biosci. 2024;13(2):196–203. [Google Scholar][Crossref]
  78. Gaballa MF. Chromobacterium violaceum strains growth conditions impacting N-Acyl Homoserine Lactones (AHL) production [Master's Thesis]. Tennessee State University; 2017. [Google Scholar][Crossref]
  79. Alfaytouri NA, Al-Ryani MA, Gaballa MF, Attitalla IH. Vulvovaginal candidiasis in pregnant women. GPH Int J Biol Med Sci. 2024;7(3):35–53. [Google Scholar][Crossref]
  80. Elyass ME, Gaballa MF, Soutiyah MAA, Abid AADM. Microbiological evaluation and chemical analysis of potable water in Al-Jabal Al-Akhdar. J Environ Sci Public Health. 2024;8(2):45–58. [Google Scholar][Crossref]
  81. Surendar AP, Palanivel KM, Saravanan S, Gopala-Krishnamurthy R. Detection and characterization of infectious bronchitis virus in desi birds by molecular assay. Int J Curr Microbiol Appl Sci. 2017;6(10):1098– 1102. [Google Scholar][Crossref]
  82. Khalil MM, Gaballa MF, Sulaiman G, Attitalla IH. Epidemiological assessment of the burden and determinants of methicillin-resistant Staphylococcus aureus (MRSA) infections in wounds. Int J Biol Med Sci. 2024;7(5):39–50. [Google Scholar][Crossref]
  83. Elhafi GE, Gaballa MF, Attitalla IH, Albakush SA. Determination of aflatoxin levels in groundnuts: A comparative study between domestic and imported seed supplies in Libya. GPH Int J Appl Sci. 2024;7(4):1–7. [Google Scholar][Crossref]
  84. Elhafi GE, Gaballa MF, Attitalla IH, Albakush SA, Albackoosh MA. Examining the health benefits of olive oil: A review tailored to the Libyan setting. GPH Int J Biol Med Sci. 2024;7(4):14–23. [Google Scholar][Crossref]
  85. Mahmoud R, Gaballa M, Alsadi I, Saleh A, Abd Alati M, Abid AA. Microbiological evaluation of retail veal meat in the city of Al Bayda, Libya. AlQalam J Med Appl Sci. 2024;8(2):335–340. [Google Scholar][Crossref]
  86. Khalil MM, Sulaiman G, Gaballa MF, Attitalla IH. Investigation of bacterial flora on mobile phones: A comparative study between healthcare workers and non-healthcare workers. J Microbiol Res. 2024;24(1):1–7. [Google Scholar][Crossref]
  87. Akhreim AA, Jadhav AU, Gaballa MF, Ahire KD, Abid AAD, Sulaiman G, et al. The contribution of stress-tolerant plant growth-promoting rhizobacteria (PGPR) from abiotic-stressed ecosystems to sustainable plant management: A comprehensive review. Front Microbiol. 2024;15:1023456. [Google Scholar][Crossref]
  88. Fouad I, Alamami H, Gaballa MF, Selem E. Production and characterization of Aspergillus terreus inulinase, using a by-product of green asparagus (Asparagus officinalis L.). Cuestiones Fisioter. 2025;54(5):847–880. [Google Scholar][Crossref]
  89. Alhudiri IM, Gaballa MF, Ebrahim FO, Ahire KD, Eltaib FI, Attitalla IH, et al. Post-acute COVID-19 pathophysiology: Cellular stress responses, immune dysregulation, and biochemical signatures in recovery phase. Cell Physiol Biochem. 2025;59(4):485–495. [Google Scholar][Crossref]
  90. Gaballa MF, Soutiyah MAA, Abid AAD, Attitalla IH. Distribution, abundance, and environmental responses of Actinobacteria in rhizospheric and bulk soils of Al-Haniya, Libya. Acta Biol Forum. 2025;12(3):45–58. [Google Scholar][Crossref]
  91. Attitalla IH, Gaballa MF, ALraaydi NS, Abid AAD. Exploring the antimicrobial capabilities of date palm seed essential oil. Microbiol Arch. 2024;8(2):112– 120. [Google Scholar][Crossref]

How to Cite

Hassan, M. Y. A., Gaballa, M. F., ZIDAN, M. E. K., Abid, A. A. D. M., & Attitalla, I. H. (2025). Lactobacillus Probiotics: Mechanisms, Health Benefits, and Applications in Combating Pathogenic Bacteria. International Journal of Medical and All Body Health Research, 6(3), 208-216.

Hassan, Mohamed Younes A, et al. "Lactobacillus Probiotics: Mechanisms, Health Benefits, and Applications in Combating Pathogenic Bacteria." International Journal of Medical and All Body Health Research, vol. 6, no. 3, 2025, pp. 208-216.

Hassan, M. Y. A., Gaballa, M. F., ZIDAN, M. E. K., Abid, A. A. D. M. and Attitalla, I. H. (2025) 'Lactobacillus Probiotics: Mechanisms, Health Benefits, and Applications in Combating Pathogenic Bacteria', International Journal of Medical and All Body Health Research, 6(3), pp. 208-216.

Hassan MYA, Gaballa MF, ZIDAN MEK, Abid AADM, Attitalla IH. Lactobacillus Probiotics: Mechanisms, Health Benefits, and Applications in Combating Pathogenic Bacteria. International Journal of Medical and All Body Health Research. 2025;6(3):208-216.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.